---
figid: PMC11117924__antioxidants-13-00594-g005
figtitle: IL-6 signaling pathway and the mechanism of action of tolicizumab
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11117924
filename: PMC11117924__antioxidants-13-00594-g005.jpg
figlink: /pmc/articles/PMC11117924/figure/F5
number: F5
caption: 'The IL-6 signaling pathway and the mechanism of action of tolicizumab. Through
  a receptor composed of signal transduction subunit glycoprotein 130 (gp130) and
  the auxiliary transmembrane protein IL-6 receptor (IL-6R), IL-6 activates the JAK/STAT
  axis, while the MAPK cascade and the PI3K/Akt axis are activated by the domain SHP2.
  Tolicizumab antagonizes the subunit gp130. Akt: Ak strain transforming (also known
  as protein kinase B, PKB); IL-6: interleukin-6; IL-6R: IL-6 receptor; gp130: glycoprotein
  130; JAK: Janus kinase; MAPK: mitogen-activated protein kinase; PI3K: phosphoinositide
  3-kinases; SHP2: src homology phosphotvrosvlphosphatase 2; STAT: signal transducer
  and activator of transcription'
papertitle: 'Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune
  Mechanisms'
reftext: Qi Tang, et al. Antioxidants (Basel). 2024 May;13(5).
year: '2024'
doi: 10.3390/antiox13050594
journal_title: Antioxidants
journal_nlm_ta: Antioxidants (Basel)
publisher_name: MDPI
keywords: diabetic retinopathy | oxidative stress | reactive oxygen species | epigenetic
  changes | anti-VEGF drugs | corticosteroids
automl_pathway: 0.9530355
figid_alias: PMC11117924__F5
figtype: Figure
redirect_from: /figures/PMC11117924__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11117924__antioxidants-13-00594-g005.html
  '@type': Dataset
  description: 'The IL-6 signaling pathway and the mechanism of action of tolicizumab.
    Through a receptor composed of signal transduction subunit glycoprotein 130 (gp130)
    and the auxiliary transmembrane protein IL-6 receptor (IL-6R), IL-6 activates
    the JAK/STAT axis, while the MAPK cascade and the PI3K/Akt axis are activated
    by the domain SHP2. Tolicizumab antagonizes the subunit gp130. Akt: Ak strain
    transforming (also known as protein kinase B, PKB); IL-6: interleukin-6; IL-6R:
    IL-6 receptor; gp130: glycoprotein 130; JAK: Janus kinase; MAPK: mitogen-activated
    protein kinase; PI3K: phosphoinositide 3-kinases; SHP2: src homology phosphotvrosvlphosphatase
    2; STAT: signal transducer and activator of transcription'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL6
  - IL6ST
  - NM
  - LRPPRC
  - IL6R
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - PTPN11
  - STAT3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - SOAT1
  - STAT1
  - STAT2
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
---
